Rheumatology Reports https://www.pagepress.org/journals/index.php/rr <p><strong>Rheumatology Reports</strong> is an international, open access, peer-reviewed journal publishing high quality papers about any rheumatological condition, musculoskeletal medicine and surgery. The journal welcomes papers on clinical, translational or basic research (in humans and in experimental model systems) that improve rheumatology clinical practice or enhance current understanding of rheumatic disease mechanisms. <strong>Rheumatology Reports</strong> aims to provide rapid publication of accepted papers and to give accurate scientific feed-back to all submissions by experts in the field.</p> PAGEPress Scientific Publications, Pavia, Italy en-US Rheumatology Reports 2036-7511 <p><strong>PAGEPress</strong> has chosen to apply the&nbsp;<a href="http://creativecommons.org/licenses/by-nc/4.0/" target="_blank" rel="noopener"><strong>Creative Commons Attribution NonCommercial 4.0 International License</strong></a>&nbsp;(CC BY-NC 4.0) to all manuscripts to be published.<br><br> An Open Access Publication is one that meets the following two conditions:</p> <ol> <li>the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.</li> <li>a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.</li> </ol> <p>Authors who publish with this journal agree to the following terms:</p> <ol> <li>Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</li> <li>Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.</li> <li>Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.</li> </ol> A rare hereditary disease: Muckle-Wells syndrome https://www.pagepress.org/journals/index.php/rr/article/view/6535 Cryopyrin associated periodic syndrome (CAPS) is a dominantly-inherited autoinflammatory disease, which is included in the group of periodic fever syndromes. It is caused by a defect in the regulation of inflammatory cytokines, particularly interleukin-1β. CAPS encompasses a spectrum of three phenotypes of increasing severity: familial cold autoinflammatory syndrome, Muckle-Wells syndrome (MWS) and neonatal onset multisystem inflammatory disease. We report the case of a 58-year-old male, who had migratory joint pains, daily urticaria, chills, and episodic conjunctivitis since childhood and hearing loss in his 20s with a family history of similar symptoms. He was diagnosed with MWS after being found to have a <em>R262W</em> gene mutation in <em>NLRP3</em> gene and successfully treated with canakinumab. After his discovery, other 1<sup>st</sup> and 2<sup>nd</sup> degree family members with similar complaints were found to have the same genetic mutation and were also successfully treated with canakinumab. Nitya Ramreddy Aviva Hopkins Carlos Lozada ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2016-08-18 2016-08-18 8 1 10.4081/rr.2016.6535 Pulsed radiofrequency therapy might be not inferior to thermal neurotomy in lumbar facet joint pain: a commentary https://www.pagepress.org/journals/index.php/rr/article/view/6167 The effects of pulsed radiofrequency treatment in low back pain was evaluated in a routine clinical setting and compared with thermal neurotomy of nerve structures of the facet joint. The treatment of 19 patients with lumbar facet joint pain was prospectively evaluated. Follow-ups were recorded at 6 weeks and 6 months after intervention. Patients with ≥50% pain relief following controlled diagnostic local anesthetic block underwent medial branch neurotomy with thermal continuous radiofrequency (CRF, n=16) or pulsed radiofrequency (PRF, n=3). Experiences between the two radiofrequency modes in the treatment of facet joint pain were recorded. In the overall population, a facet joint pain reduction of 23% at 6 weeks, 20% at 6 months and an improvement in various clinical scores was achieved. CRF and PRF appeared to be similarly effective in the treatment of facet joint pain, providing pain relief for at least 6 months. These observations should encourage pain researcher to design meaningful studies to further address this concept. Haiko Sprott Norina Bergamin Armin Aeschbach ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2016-08-18 2016-08-18 8 1 10.4081/rr.2016.6167 Systemic lupus erythematosus and extreme thrombocytosis without autosplenectomy https://www.pagepress.org/journals/index.php/rr/article/view/6035 Systemic Lupus Erythematosus (SLE) is an autoimmune disorder characterized by multiorgan system involvement. Hematologic manifestations are common in SLE and include thrombocytopenia in as many as 50% of patients. Thrombocytosis is much less common in SLE, occurring in less than 5% of patients, and is typically reported in association with autosplenectomy. The following case report describes a 35-year-old female patient who presented for evaluation with extreme thrombocytosis of unclear etiology. The patient was diagnosed with reactive thrombocytosis due to active SLE for which treatment with corticosteroids and plaquenil was provided with subsequent decline in platelet counts. This report highlights the importance of considering SLE in the differential for thrombocytosis despite its classic association with thrombocytopenia. Austin Anderson ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2015-12-30 2015-12-30 8 1 10.4081/rr.2015.6035 Successful treatment of neuro-Behçet’s disease with infliximab: four years follow-up https://www.pagepress.org/journals/index.php/rr/article/view/6115 Neuro-Behçet’s disease (NBD) is a rare but severe manifestation of Behçet’s disease. Patients with NBD tend to have high morbidity and mortality. Some patients do not respond adequately to conventional therapy (corticosteroids and immunosuppressants). This has led to treatment gaps in the therapy of NBD. There are reports in the literature of patients with Behçet’s disease responding to anti-TNF therapy. We present a case of a male patient with biopsy proven cerebral vasculitis presenting as NBD who has been in remission with near resolution of cerebral magnetic resonance imaging lesions for 4 years following treatment with infliximab and azathioprine. Manjinder Kaur Emily S. Nia Rebecca A. Millius Dominick G. Sudano Jeffrey R. Lisse ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2015-10-20 2015-10-20 8 1 10.4081/rr.2015.6115